Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Nutraplus India Ltd (524764)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524764 NSE: Pharmaceuticals & Drugs | Small Cap | Nutraplus India Share Price
₹2.10 0.00 (0.00%)
As on 13-Dec'21 18:01
Nutraplus India Ltd (524764)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524764 NSE: Pharmaceuticals & Drugs | Small Cap | Nutraplus India Share Price
₹2.10 0.00 (0.00%)
As on 13-Dec'21 18:01
Key Metrics
Valuation Multiples
Market Cap
₹7 Cr.
Current Price
₹2.1
52-Week Low / High
₹2 / 2
TTM EPS
₹0.1
TTM Sales
₹69.8 Cr.
Book Value per Share
₹13.5
P/E Ratio
15.63
Industry PE
54.2
Price to Book (P/B)
0.16
Price to Sales (P/S)
0.10
EV/EBITDA
6.81
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-13.46%
Return on Capital Employed (ROCE)
-1.65%
Return on Assets (ROA)
-4.29%
Operating Profit Margin
4.9%
Net Profit Margin
-6.24%
Gross Profit Margin
-1.5%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-68.6%
Net Profit Growth (1 Year)
-
-229.71%
Asset Quality
Promoter Holding
40.07%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹31 Cr.
Equity
₹17.1 Cr.
Face Value
₹5
All Time Low / High
₹0.27 / 224.73
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 10.8% | -2.9% | 4.1% | 7.2% | -33.4% | -37.2% | 0% | 0% | 0% | 0% | - |
| Value Creation Index ⓘ | -0.2 | -1.2 | -0.7 | -0.5 | -3.4 | NA | NA | NA | NA | NA | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 77.6 | 91 | 109 | 140 | 107 | 0 | 0.1 | 0 | 0 | 0 | 107 |
| Sales YoY Gr. | - | 17.3% | 19.9% | 27.9% | -23.6% | -100% | 400% | -100% | NA | NA | - |
| Adj EPS ⓘ | 2.6 | -2.1 | 0 | 0.4 | -13.2 | -1.9 | -0.9 | -0.1 | -0 | -0 | -14 |
| YoY Gr. | - | -183.1% | NA | 1200% | -3482.1% | NA | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | 20.9 | 19.7 | 19.7 | 20.4 | 6.3 | -0.6 | -1.5 | -1.5 | -1.6 | -1.6 | 6.3 |
| Adj Net Profit ⓘ | 7.1 | -7.2 | 0.1 | 1.3 | -45 | -6.4 | -3 | -0.2 | -0.1 | -0.1 | -48 |
| Cash Flow from Ops. ⓘ | -9.6 | 19.7 | 6.7 | 12.4 | 9.1 | -14.3 | -0.2 | 0 | -0 | 0 | - |
| Debt/CF from Ops. ⓘ | -7.5 | 3.4 | 11 | 6.1 | 8.4 | -0.1 | -10.1 | 105.7 | -225.4 | 1000.3 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -100% | -100% | -100% | NA | ||||
| Adj EPS ⓘ | -154% | NA | NA | NA | ||||
| BVPSⓘ | -175% | -175.6% | NA | NA | ||||
| Share Price | -25.4% | 1.3% | - | - | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 12.9 | -11.1 | 0.1 | 2 | -98.8 | -65.5 | 85 | 3 | 1.2 | 0.9 | -588.3 |
| Op. Profit Mgn % ⓘ | 15.7 | -2.1 | 8.5 | 9.2 | -29.8 | -1820.2 | -3724.4 | 0 | 0 | 0 | NAN |
| Net Profit Mgn % ⓘ | 9.2 | -8 | 0.1 | 1 | -42.2 | -32641.1 | -3091.9 | 0 | 0 | 0 | -44.9 |
| Debt to Equity ⓘ | 1.2 | 1 | 1.1 | 1.1 | 3.5 | -0.9 | -0.3 | -0.3 | -0.3 | -0.3 | - |
| Working Cap Days ⓘ | 314 | 295 | 243 | 150 | 117 | 2,41,116 | 26,608 | 0 | 0 | 0 | 0 |
| Cash Conv. Cycle ⓘ | 32 | 56 | 45 | 41 | 41 | 44,197 | 8,264 | 0 | 0 | 0 | 0 |
Valuation of Nutraplus India - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'12 | Mar'14 | Mar'15 |
|---|---|---|---|
| Sales | 44.71 | 61.69 | 65.04 |
| Operating Expenses ⓘ + | 38.46 | 51.50 | 61.85 |
| Operating Profit ⓘ | 6.25 | 10.19 | 3.20 |
| Operating Profit Margin (%) | 14.0% | 16.5% | 4.9% |
| Other Income ⓘ + | 0.17 | 0.10 | 0.20 |
| Interest ⓘ | 1.55 | 3.57 | 4.52 |
| Depreciation ⓘ | 0.63 | 1.61 | 1.40 |
| Profit Before Tax ⓘ | 4.24 | 5.11 | -5.65 |
| Tax ⓘ | 1.30 | 1.98 | -1.59 |
| Profit After Tax | 2.94 | 3.13 | -4.06 |
| PAT Margin (%) | 6.6% | 5.1% | -6.2% |
| Adjusted EPS (₹) | 2.6 | 2.4 | -1.7 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% |
| PARTICULARS | Mar'12 | Mar'14 | Mar'15 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 12.78 | 20.25 | 41.76 | ||||||||
| Debt + | 12.98 | 28.78 | 35.65 | ||||||||
| Minority Interest | 0 | 0 | 0 | ||||||||
| Trade Payables | 12.51 | 19.07 | 24.21 | ||||||||
| Others Liabilities ⓘ | 6.21 | 7.14 | 12.46 | ||||||||
| Total Liabilities ⓘ | 44.48 | 75.24 | 114.07 | ||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 19.49 | 35.67 | 22.95 | ||||||||
| CWIP ⓘ | 0.05 | 1.04 | 13.42 | ||||||||
| Investments ⓘ | 1.62 | 0 | 4.15 | ||||||||
| Inventories | 6.82 | 19.26 | 17.38 | ||||||||
| Trade Receivables | 12.06 | 14.77 | 13.38 | ||||||||
| Cash Equivalents | 1.37 | 1.48 | 11.42 | ||||||||
| Others Assets ⓘ | 3.07 | 3.02 | 31.37 | ||||||||
| Total Assets ⓘ | 44.48 | 75.24 | 114.07 | ||||||||
| PARTICULARS | Mar'14 | Mar'15 |
|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 3.98 | -16.48 |
| Cash Flow From Investing Activity ⓘ + | -10.82 | -5.10 |
| Cash Flow From Financing Activity ⓘ + | 6.85 | 31.53 |
| Net Cash Flow ⓘ | 0.01 | 9.94 |
| PARTICULARS | Mar'12 | Mar'14 | Mar'15 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 23.03 | 18.98 | -13.46 | |||||||
| ROCE (%) | 20.93 | 21.85 | -1.65 | |||||||
| Asset Turnover Ratio | 1.08 | 1.14 | 0.76 | |||||||
| PAT to CFO Conversion(x) | 1.35 | -5.27 | N/A | |||||||
| Working Capital Days | ||||||||||
| Receivable Days | 91.50 | 71.60 | 71.10 | |||||||
| Inventory Days | 51.70 | 69.60 | 92.60 | |||||||
| Payable Days | 149.90 | 138.90 | 167.10 | |||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Nutraplus India Ltd FAQs
The current trading price of Nutraplus India on 13-Dec-2021 18:01 is ₹2.10.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Dec-2021 the market cap of Nutraplus India stood at ₹7.16 Cr
The latest P/E ratio of Nutraplus India as of 12-Dec-2021 is 0.00.
The latest P/B ratio of Nutraplus India as of 12-Dec-2021 is 0.33.
The 52-week high of Nutraplus India is ₹2.10 and the 52-week low is ₹1.90.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Nutraplus India is ₹107 ( Cr.) .
Data is not available for this company.
The key valuation ratios of Nutraplus India Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
No data found
About Nutraplus India Ltd
Nutraplus Products India (NPIL) was incorporated as a private limited company in February 1990. The company's manufacturing unit was commissioned to make APIs and intermediates in 1995. Various products were made earlier. For a fine organic chemical manufacturing unit, the first 6 to 7 years period was crucial in a sense that proficiency in handling certain unit processes were developed. Based on such expertise, higher value and profitable products then could be taken up. In spite of liberalization of imports, reduction in import duties and indigenous competition, the company has withstood uncertainties.
The company intends to take up manufacture of an API and its intermediates by way of expansion of fixed assets. Up till now, the company adopted a stringy to carry out job working and also make selected products for a merchant exporter on fixed quantity and rate. The products made by the company hence, were exported by the merchant exporter.
The registered office of the company is located at 7- A Vakil Villa, H F Society Road End, Jogeshwari E Mumbai, Maharashtra 400060.
Product of the company
- N Bromo Succinimide
- N Methyl Nitro Guanidine
- Chlorhexidine Gluconate
- 7- Chloro Quinaldine
- M Bromo Anisole
You have 36 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
